STOCK TITAN

Surgery Partners (SGRY) files Form 144 for 150,000-share sale via UBS

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • Planned sale of 150,000 shares with an aggregate market value of $3,294,454.97 filed for sale on 09/18/2025 through UBS.
  • Multiple recent insider sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including two transactions of 100,000 shares, indicating substantial insider disposition activity.

Insights

TL;DR: Significant insider selling reported; timing aligns with option exercise and immediate sale through UBS.

The filing shows an insider exercising equity compensation and proposing an immediate sale of 150,000 common shares valued at about $3.29 million. Prior transactions by Wayne DeVeydt between late August and mid-September 2025 document repeated disposals of company stock, including two large 100,000-share transactions. From a trading-flow perspective, this pattern reflects exercise-and-sell activity rather than a single isolated sale; investors should note the volume but the filing does not state any nonpublic adverse information or change in company operations.

TL;DR: Recurrent insider sales and same-day exercise-and-sell warrant governance attention.

The report evidences equity option exercise on 09/18/2025 followed by a proposed sale the same day, and a series of recent dispositions by an individual (Wayne DeVeydt). While such behavior is common with option liquidity, repeated large sales can raise questions about insider alignment with shareholders. The filing, however, contains the standard attestation that no material undisclosed information is known to the seller; no further governance disclosures are provided within this form.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by Surgery Partners (SGRY) report?

The Form 144 reports a proposed sale of 150,000 common shares valued at $3,294,454.97, acquired via equity compensation and listed for sale on 09/18/2025 through UBS on NASDAQ.

Who acquired the shares being offered and how were they acquired?

The shares were acquired on 09/18/2025 by the reporting person through an equity option exercise from Surgery Partners, Inc.

Has the filer recently sold other Surgery Partners shares?

Yes. The filing lists multiple sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including sales of 100,000 shares on 08/21/2025 and 09/11/2025 with listed gross proceeds.

Through which broker is the proposed sale being executed?

The proposed sale is to be executed through UBS Financial Services Inc, located at 1000 Harbor Blvd, Weehawken, NJ, and listed for sale on NASDAQ.

Does the Form 144 indicate any undisclosed material information about Surgery Partners?

The signer represents by the notice signature that they do not know any material adverse information about the issuer that has not been publicly disclosed; the filing contains no additional disclosures of nonpublic information.